Herve Affagard, Co-founder and CEO of
'
An innovative therapeutic approach based on microbiome modulation to improve survival in patients with liquid and solid tumors
The gut microbiota is an assembly of rich and diverse microorganisms ('ecosystem') and contributes to maintaining a symbiosis[2] between the host and the billions of naturally present microbes in the human body. This symbiosis is essential for human health and regulates our immune homeostasis, as 80% of immune cells reside in the intestine[3], and our metabolism. A balanced symbiosis generates protection through a stronger intestinal barrier and contributes to the education and maturation of the immune system against potential pathogens. However, lifestyle, diet, or the use of toxic drugs for the microbiome can alter this symbiosis. This alteration is referred as 'dysbiosis' and is notably illustrated by a loss of diversity of microorganisms. This condition represents a danger for the host because bacteria could induce deleterious, inflammatory reactions or make anti-cancer treatments less effective.
To address significant unmet medical needs in oncology,
MaaT013 for the treatment of acute Graft-versus-Host Disease (aGvHD), ready to enter Phase III trial in the EU[4] (application of the clinical trial submitted). MaaT013 is also expected to enter a Phase II proof of concept trial to evaluate its impact on response rates to immune checkpoint inhibitors in treatment-naive metastatic melanoma.
MaaT033 for the improvement of survival in patients with acute myeloid leukemia (AML) or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), currently in a Phase Ib trial.
MaaT03X, a new generation of co-fermented microbiome-based therapies to be used in combination with immuno-therapy in oncology, targeting solid tumors. The MaaT03X line is currently in preclinical testing.
Forward Looking Data
This press release contains forward-looking statements, including statements about the expected closing of the Offering and the anticipated use of proceeds from the Offering. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the Company regarding the intended results of its strategy. By their nature, these forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Factors that could cause actual results to differ materially from those described or projected herein include risk associated with market and other financing conditions, risks associated with clinical trials and regulatory reviews and approvals, and risk related to the sufficiency of the Company's existing cash resources and liquidity. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorite des Marches Financiers. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date. The Company undertakes no obligation to update or revise forward-looking statements as a result of new information, future events or circumstances, or otherwise, except as required by law.
Disclaimer
This announcement is not being made in and copies of it may not be distributed or sent, directly or indirectly, into
The distribution of this document may be restricted by law in certain jurisdictions countries or constitute a breach of applicable law. Persons into whose possession this document comes are required to inform themselves about and to observe such restrictions. The information contained in this document does not constitute an offer of securities for sale in
No communication and no information in respect of the issue, offering and placement by the Company of its shares (the 'Shares') may be distributed to the public in any jurisdiction where a registration or approval is required. No steps have been or will be taken outside of
This announcement is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the
This information does not contain a solicitation for money, securities or other consideration and, if sent in response to the information contained herein, will not be accepted.
For
This announcement, the information set forth herein or the prospectus referenced herein do not constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in
For the EEA:
With respect to the Member States of the European Economic Area other than
For the purposes of this paragraph, the notion of an 'offer to the public of Shares' in each of the relevant Member States, means any communication to persons in any form and by any means, presenting sufficient information on the terms of the offer and the Shares to be offered, so as to enable an investor to decide to purchase or subscribe for those securities.
This selling restriction comes in addition to the other selling restrictions applicable in the relevant Member States.
This announcement is solely an advertisement and does not constitute a prospectus within the meaning of Regulation (EU) 2017/1129 of the
For the
In the
For
Copies of the Prospectus are available, free of charge, from the Company's registered office (70 Avenue
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ('MiFID II'); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the 'MiFID II Product Governance Requirements'), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any 'manufacturer'(for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares offered in the offering (the 'Offered Shares') have been subject to a product approval process, which has determined that the Offered Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the 'Target Market Assessment'). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Offered Shares may decline and investors could lose all or part of their investment; the Offered Shares offer no guaranteed income and no capital protection; and an investment in the Offered Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom.
The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering.
For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment for any particular client of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Offered Shares.
Each distributor is responsible for undertaking its own target market assessment in respect of the shares and determining appropriate distribution channels.
For the avoidance of doubt, even if the target market includes retail investors, the manufacturers and the distributors have decided they will only procure investors for the Offered Shares who meet the criteria of eligible counterparties and professional clients.
Contact:
Headquarter
70 Avenue
69007 Lyon
T: 04 28 29 14 00
Manufacturing
317 Avenue
69007 Lyon
T: 04 28 29 14 01
(C) 2021 Electronic News Publishing, source